A Universal Platform for Transdermal Drug Delivery
OUR Mission


Avro is a leading preclinical stage pharmaceutical company developing OmniDerm(™)
a platform transdermal technology for the passive delivery of small drug molecules. 

Avro’s novel polymer utilizes cutting-edge advances in biomaterials engineering and micro-encapsulation technology, to hold and deliver a wide range of drugs over a 1-7 day timespan, where transdermal delivery was previously thought to be impossible. 

Our mission is to improve patient health outcomes and quality of life through medication compliance and adherence afforded by effective drug delivery solutions.

To learn more, or chat about partnering, send us a note at: partnering@avrolifesci.com

OUR Solution

Accessible Transdermal Tech

One Size Fits All

One-size-fits-all versatile platform allowing for encapsulation and delivery of a wide variety of different small molecule drugs, inplace of existing “lock and key” patches available on the market, requiring a custom polymer for each drug.

Cost-effective Manufacturing

Cost-effective, tunable, and easily scalable manufacturing processes using easily sourced and non-irritant, non-toxic materials and known industrial methods. Results in a single layer, drug-in-adhesive, sweatproof, waterproof, non-irritant patch with few failure modes during production due to the polymer’s fundamental chemistry.

Eliminating Complex Systems

Relies on fundamental materials science breakthroughs enabled by recent advances in understanding of biomaterial interactions and microencapsulation methods. Eliminates the need for expensive microneedles, lock and key patches, and complex manufacturing processes, allowing Avro to succeed where pharma has failed


Shakir Lakhani
Co-founder, CEO
Keean Sarani
Co-founder, COO
Frank LaRonde MD, PhD
Senior Scientist
Samantha Shortall
Mahdi Roohnikan
Shirley Wang
Research Associate
Drew Davidson
Research Associate
Andrew Mendonca
Research Associate


Dr. Christopher Rhodes
CEO, Drug Delivery Experts, Prev. Exec. Director of Pharmaceutical R&D at Amylin Pharmaceuticals
Alasdair Thong
Prev. Director of Bayer AG Venture Investments, Investor at Index Ventures, Founding team at Medicxi
Dr. James Wright
Prev. Founder of Civitas Therapeutics (acq. by Acorda Tx for $525M), SVP at Alkermes, VP of Pharmaceutical Sciences at Takeda
Dr. Elizabeth Iorns
CEO of Science Exchange, Stanford Med METRICS Advisory Board member, YC Expert
Dr. Maleek Jamal
Prev. Lead, BCG Healthcare Practice, Clinical Trials Lead at P&G
Dr. Muhammad Mamdani
Director of Li Ka Shing Centre at St. Michael’s Hospital, Prev. Director of US Outcomes Research at Pfizer
Who Supports us


Y CombinatorY CombinatorY CombinatorY CombinatorY CombinatorY Combinator

Contact Us

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.